CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.220
0.00 (0.05%)
Jan 23, 2025, 4:00 PM EST
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
268.61M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
CytoDyn News
- 5 weeks ago - December 2024 Letter to Shareholders - GlobeNewsWire
- 2 months ago - CytoDyn Phase 2 study of leronlimab cleared by FDA - Seeking Alpha
- 2 months ago - CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial - GlobeNewsWire
- 3 months ago - CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories - GlobeNewsWire
- 3 months ago - CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques - GlobeNewsWire
- 3 months ago - CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial - GlobeNewsWire
- 4 months ago - CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - GlobeNewsWire
- 4 months ago - September 2024 Letter to Shareholders - GlobeNewsWire